Blue Crest Capital Management LTD Geron Corp Transaction History

Blue Crest Capital Management LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$0.98 - $1.85 $18,770 - $35,434	-19,154 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$1.76 - $6.38 $17,084 - $61,930	-9,707 Reduced 33.63%	19,154 $34,000
Q2 2018 Aug 14, 2018	BUY	$3.29 - $4.82 $21,684 - $31,768	6,591 Added 29.6%	28,861 $99,000
Q1 2018 May 15, 2018	BUY	$1.81 - $5.98 $40,308 - $133,174	22,270 New	22,270 $95,000
Q4 2017 Feb 14, 2018	SELL	$1.8 - $2.32 $21,382 - $27,559	-11,879 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$1.99 - $2.65 $23,639 - $31,479	11,879	11,879 $26,000

287

492M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.05B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Blue Crest Capital Management LTD with notifications on news.